High-sensitivity cardiac troponin assays will enable more rapid diagnosis of acute myocardial infarction and risk stratification, but clinicians must understand the new facets and issues introduced by these assays.
Answers are grounded in this paper and cite their sources.
Demands clinician education on hs-cTn assay issues in acute care; leaves open optimal implementation thresholds and protocols.
In the not too distant future, high-sensitivity cardiac troponin assays will be introduced for use in the United States. They bring with them many exciting new opportunities within cardiovascular practice including the ability to confirm or refute a diagnosis of acute myocardial infarction more rapidly as well as the ability to risk stratify and guide treatment decisions in patients with a variety of acute and chronic noncoronary diseases. However, clinicians and researchers must be aware of the new facets introduced with troponin testing and, in particular, the new issues that will arise with high sensitivity assays. Emphasis must also be placed on reiterating the same principles of the effective use of troponin testing that applied to conventional assays, as these are likely to become even more important. This review outlines a number of important issues related to high sensitivity assays with a focus on their use in acute hospital settings.
No takes yet. Share an insight, caveat, or question.
Sara et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: